Moupali Das

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women”.

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

New England Journal of Medicine(2024)10.1056/nejmoa2407001

N/A

17.7DataRank · unranked

473 citations

Moupali Das, Quarraisha Abdool Karim, Khatija Ahmed, Joanne Batting, William Brumskine +35 more

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

The Lancet(2020)10.1016/s0140-6736(20)31065-5

N/A

13.0DataRank · unranked

427 citations

Jean-Michel Molina, Melanie A Thompson, Peter L Anderson, Karam C Mounzer, Joss J De Wet +19 more

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial

The Lancet HIV(2018)10.1016/s2352-3018(18)30010-9

N/A

0.933DataRank · unranked

27 citations

Frank A Post, Edwin DeJesus, Daniel Podzamczer, Giovanni Di Perri, Vicente Estrada +12 more

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results

JAIDS Journal of Acquired Immune Deficiency Syndromes(2017)10.1097/qai.0000000000001350

N/A

0.716DataRank · unranked

117 citations

Melanie Thompson, Paul E. Sax, Bernhard Haas, Cheryl McDonald, David A. Wohl +10 more

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

Clinical Infectious Diseases(2021)10.1093/cid/ciab444

N/A

0.714DataRank · unranked

116 citations

Christoph C Carter, Kathleen Melbourne, Todd T. Brown, Cal Cohen, Moupali Das +14 more

HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad507

N/A

0.168DataRank · unranked

2 citations

Stephen R. Cole, Jessie K. Edwards, David V. Glidden, Moupali Das, Bonnie E. Shook‐Sa +5 more

Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies

Clinical Infectious Diseases(2024)10.1093/cid/ciae143

N/A

0DataRank · unranked

19 citations

Tao Li, Juan Yang, Melanie de Boer, Christoph C Carter, Moupali Das +58 more

Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project

Clinical Pharmacology & Therapeutics(2022)10.1002/cpt.2830

N/A

0DataRank · unranked

20 citations

Fei Gao, Eduard Grebe, Amy Cutrell, Moupali Das, Deborah Donnell +9 more